📣 VC round data is live. Check it out!

Tenaya Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Tenaya Therapeutics and similar public comparables like ProQR Therapeutics, Protalix, Orthocell, AN2 Therapeutics and more.

Tenaya Therapeutics Overview

About Tenaya Therapeutics

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.


Founded

2016

HQ

United States

Employees

97

Financials (LTM)

Revenue: $3M
EBITDA: ($78M)

EV

$83M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Tenaya Therapeutics Financials

Tenaya Therapeutics reported last 12-month revenue of $3M and negative EBITDA of ($78M).

In the same LTM period, Tenaya Therapeutics generated $1M in gross profit, ($78M) in EBITDA losses, and had net loss of ($89M).

Revenue (LTM)


Tenaya Therapeutics P&L

In the most recent fiscal year, Tenaya Therapeutics reported revenue of — and EBITDA of ($85M).

Tenaya Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Tenaya Therapeutics
LTMLast FY202320242025202620272028
Revenue$3M————
Gross Profit$1M————
Gross Margin40%————
EBITDA($78M)($85M)($123M)($107M)($85M)
EBITDA Margin(2719%)————
EBIT Margin(3144%)————
Net Profit($89M)($91M)($124M)($111M)($91M)
Net Margin(3124%)————

Financial data powered by Morningstar, Inc.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics has current market cap of $173M, and enterprise value of $83M.

Market Cap Evolution


Tenaya Therapeutics' stock price is $0.80.

Tenaya Therapeutics share price increased by 15.4% in the last 30 days, and by 73.3% in the last year.

Tenaya Therapeutics has an EPS (earnings per share) of $-0.42.

See more trading valuation data for Tenaya Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$83M$173M12.9%15.4%42.1%73.3%$-0.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Tenaya Therapeutics Valuation Multiples

Tenaya Therapeutics trades at 29.2x EV/Revenue multiple, and (1.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Tenaya Therapeutics

EV / Revenue (LTM)


Tenaya Therapeutics Financial Valuation Multiples

As of May 5, 2026, Tenaya Therapeutics has market cap of $173M and EV of $83M.

Tenaya Therapeutics has a P/E ratio of (1.9x).

LTMLast FY202320242025202620272028
EV/Revenue29.2x————
EV/EBITDA(1.1x)(1.0x)(0.7x)(0.8x)(1.0x)
EV/EBIT(0.9x)(0.9x)(0.6x)(0.7x)(0.9x)
EV/Gross Profit72.9x————
P/E(1.9x)(1.9x)(1.4x)(1.6x)(1.9x)
EV/FCF—(1.2x)(0.8x)(0.9x)(1.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Tenaya Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Tenaya Therapeutics Margins & Growth Rates

See estimated margins and future growth rates for Tenaya Therapeutics

Tenaya Therapeutics Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth(12%)(21%)
EBIT Growth(12%)(20%)
Net Profit Growth(10%)(18%)
FCF Growth(11%)(25%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Tenaya Therapeutics Operational KPIs

Tenaya Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Access forward-looking KPIs for Tenaya Therapeutics
LTMLast FY202620272028
Rule of 40(2627%)—
Bessemer Rule of X(2489%)—
Revenue per Employee—$0.0M
Opex per Employee—$1.0M
G&A Expenses to Revenue986%—
R&D Expenses to Revenue2436%—

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Tenaya Therapeutics Competitors

Tenaya Therapeutics competitors include ProQR Therapeutics, Protalix, Orthocell, AN2 Therapeutics, Vytrus Biotech, Panion & Bf Biotech, Tetratherix, Tiziana Life Sciences, Satellos Bioscience and Hyloris Pharmaceuticals.

Most Tenaya Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
ProQR Therapeutics4.5x3.9x(1.8x)(2.3x)
Protalix2.8x2.4x(50.7x)—
Orthocell23.1x16.0x(26.7x)(17.6x)
AN2 Therapeutics——(3.1x)—
Vytrus Biotech17.1x15.7x34.5x31.2x
Panion & Bf Biotech2.8x—12.9x—
Tetratherix—46.3x—(29.8x)
Tiziana Life Sciences——(10.2x)—

This data is available for Pro users. Sign up to see all Tenaya Therapeutics competitors and their valuation data.

Start Free Trial

Tenaya Therapeutics Funding History

Before going public, Tenaya Therapeutics raised $248M in total equity funding, across 3 rounds.

Last private valuation of Tenaya Therapeutics was $210M, after raising $106M in March 2021 from Casdin Capital, Fidelity, GV, and 4 other investors.


Tenaya Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-21Series CCasdin Capital; Fidelity; GV; RA Capital Management; RTW Investments; T. Rowe Price; The Column Group$106M$210MTenaya Therapeutics is a Bay Area biotech company developing therapies to address cardiovascular disease, focusing on gene therapy, cellular regeneration, and precision medicine. In 2019, the company raised $92 million at a $210 million valuation. It later completed a $106 million Series C round led by RTW Investments, with participation from investors including Casdin Capital, Fidelity, GV, RA Capital Management, T. Rowe Price, and The Column Group, matching the query details around early 2021. Tenaya went public in July 2021 with a $180 million IPO.
Oct-19Series BCasdin Capital; Greenspring Associates; GV; The Column Group$92M—Tenaya Therapeutics is a biotechnology company developing disease-modifying therapies for heart disease, with a pipeline including TN-201 and TN-401 gene therapies targeting proteins for conditions like PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The company focuses on iPSC disease models, capsid engineering, cardiac-specific promoters, and in-house AAV manufacturing. Recent collaborations include a multi-target deal with Alnylam Pharmaceuticals offering up to $10 million upfront and $1.13 billion in milestones. Financial data from SEC filings and analyses show Tenaya has had zero revenue across all reported periods, including 2019 through 2024, with quarterly revenues consistently at $0 and annual revenues at $0.00 for 2019-2024. Earnings are deeply negative, with losses escalating from -$38 million in Dec 2020 to -$94 million in Sep 2025, driven by high R&D expenses (e.g., $72 million in Sep 2025 quarter) and G&A costs. The company reports negative return on equity of -113.74% and no net margin due to unprofitability typical for clinical-stage biotechs. As of recent filings, Tenaya had approximately $63.1 million in non-affiliate equity value as of June 2025 and 216,998,876 common shares outstanding as of March 2026, with a market cap around $189 million and enterprise value of $138.59 million based on a share price of $1.16. Traction includes Phase 1b/2 data for TN-201 and TN-401 showing improved biomarkers and manageable safety, with Fast Track and Orphan Drug designations.
Dec-16Series AThe Column Group$50M—Tenaya Therapeutics, founded in 2016, is a biotech company focused on developing therapies for cardiovascular and muscular diseases, including gene therapy and small molecule programs. The company raised equity financing from investors including The Column Group, with approximately $248 million raised since inception as of its S-1 filing prior to its public listing. The Column Group remains a significant shareholder, holding over 49 million shares as of early 2026 and recently selling 4.17 million shares at prices around $0.60. Tenaya Therapeutics shows no revenue as a pre-revenue biotech, with recent 2025 net losses of $90.6 million reported. Current market valuation metrics include a price-to-book ratio of 2.2x at a $0.86 share price, considered undervalued compared to biotech peers at 5x and industry average of 2.7x. Tenaya continues clinical development, with recent TN-301 data and Alnylam collaboration driving share price volatility.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Tenaya Therapeutics

When was Tenaya Therapeutics founded?Tenaya Therapeutics was founded in 2016.
Where is Tenaya Therapeutics headquartered?Tenaya Therapeutics is headquartered in United States.
How many employees does Tenaya Therapeutics have?As of today, Tenaya Therapeutics has over 97 employees.
Who is the CEO of Tenaya Therapeutics?Tenaya Therapeutics' CEO is Faraz Ali.
Is Tenaya Therapeutics publicly listed?Yes, Tenaya Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Tenaya Therapeutics?Tenaya Therapeutics trades under TNYA ticker.
When did Tenaya Therapeutics go public?Tenaya Therapeutics went public in 2021.
Who are competitors of Tenaya Therapeutics?Tenaya Therapeutics main competitors include ProQR Therapeutics, Protalix, Orthocell, AN2 Therapeutics, Vytrus Biotech, Panion & Bf Biotech, Tetratherix, Tiziana Life Sciences, Satellos Bioscience, Hyloris Pharmaceuticals.
What is the current market cap of Tenaya Therapeutics?Tenaya Therapeutics' current market cap is $173M.
What is the current revenue of Tenaya Therapeutics?Tenaya Therapeutics' last 12 months revenue is $3M.
What is the current revenue growth of Tenaya Therapeutics?Tenaya Therapeutics revenue growth (NTM/LTM) is 92%.
What is the current EV/Revenue multiple of Tenaya Therapeutics?Current revenue multiple of Tenaya Therapeutics is 29.2x.
Is Tenaya Therapeutics profitable?No, Tenaya Therapeutics is not profitable.
What is the current EBITDA of Tenaya Therapeutics?Tenaya Therapeutics has negative EBITDA and is not profitable.
What is Tenaya Therapeutics' EBITDA margin?Tenaya Therapeutics' last 12 months EBITDA margin is (2719%).
What is the current EV/EBITDA multiple of Tenaya Therapeutics?Current EBITDA multiple of Tenaya Therapeutics is (1.1x).
How many companies Tenaya Therapeutics has acquired to date?Tenaya Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Tenaya Therapeutics has invested to date?Tenaya Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Tenaya Therapeutics

Lists including Tenaya Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial